321 related articles for article (PubMed ID: 37442152)
1. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.
Yuen MF; Asselah T; Jacobson IM; Brunetto MR; Janssen HLA; Takehara T; Hou JL; Kakuda TN; Lambrecht T; Beumont M; Kalmeijer R; Guinard-Azadian C; Mayer C; Jezorwski J; Verbinnen T; Lenz O; Shukla U; Biermer M;
Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):790-802. PubMed ID: 37442152
[TBL] [Abstract][Full Text] [Related]
2. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
3. Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection.
Janssen HLA; Hou J; Asselah T; Chan HLY; Zoulim F; Tanaka Y; Janczewska E; Nahass RG; Bourgeois S; Buti M; Lampertico P; Lenz O; Verbinnen T; Vandenbossche J; Talloen W; Kalmeijer R; Beumont M; Biermer M; Shukla U
Gut; 2023 Jul; 72(7):1385-1398. PubMed ID: 36697207
[TBL] [Abstract][Full Text] [Related]
4. Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB.
Yuen MF; Locarnini S; Lim TH; Strasser SI; Sievert W; Cheng W; Thompson AJ; Given BD; Schluep T; Hamilton J; Biermer M; Kalmeijer R; Beumont M; Lenz O; De Ridder F; Cloherty G; Ka-Ho Wong D; Schwabe C; Jackson K; Lai CL; Gish RG; Gane E
J Hepatol; 2022 Nov; 77(5):1287-1298. PubMed ID: 35870702
[TBL] [Abstract][Full Text] [Related]
5. JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analog suppressed patients with chronic hepatitis B: REEF-2.
Agarwal K; Buti M; van Bömmel F; Lampertico P; Janczewska E; Bourliere M; Vanwolleghem T; Lenz O; Verbinnen T; Kakuda TN; Mayer C; Jezorwski J; Muenz D; Beumont M; Kalmeijer R; Biermer M; Lonjon-Domanec I
J Hepatol; 2024 Apr; ():. PubMed ID: 38583491
[TBL] [Abstract][Full Text] [Related]
6. JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection.
Zoulim F; Lenz O; Vandenbossche JJ; Talloen W; Verbinnen T; Moscalu I; Streinu-Cercel A; Bourgeois S; Buti M; Crespo J; Manuel Pascasio J; Sarrazin C; Vanwolleghem T; Shukla U; Fry J; Yogaratnam JZ
Gastroenterology; 2020 Aug; 159(2):521-533.e9. PubMed ID: 32343960
[TBL] [Abstract][Full Text] [Related]
7. Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy.
Yuen MF; Heo J; Kumada H; Suzuki F; Suzuki Y; Xie Q; Jia J; Karino Y; Hou J; Chayama K; Imamura M; Lao-Tan JY; Lim SG; Tanaka Y; Xie W; Yoon JH; Duan Z; Kurosaki M; Park SJ; Labio ME; Kumar R; Kweon YO; Yim HJ; Tao Y; Cremer J; Elston R; Davies M; Baptiste-Brown S; Han K; Campbell FM; Paff M; Theodore D
J Hepatol; 2022 Oct; 77(4):967-977. PubMed ID: 35714812
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials.
Buti M; Wong DK; Gane E; Flisiak R; Manns M; Kaita K; Janssen HLA; Op den Brouw M; Jump B; Kitrinos K; Crans G; Flaherty J; Gaggar A; Marcellin P
Lancet Gastroenterol Hepatol; 2019 Apr; 4(4):296-304. PubMed ID: 30795958
[TBL] [Abstract][Full Text] [Related]
9. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study).
Liem KS; Fung S; Wong DK; Yim C; Noureldin S; Chen J; Feld JJ; Hansen BE; Janssen HLA
Gut; 2019 Dec; 68(12):2206-2213. PubMed ID: 31462554
[TBL] [Abstract][Full Text] [Related]
10. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
[TBL] [Abstract][Full Text] [Related]
12. A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B.
van Bömmel F; Stein K; Heyne R; Petersen J; Buggisch P; Berg C; Zeuzem S; Stallmach A; Sprinzl M; Schott E; Pathil-Warth A; von Arnim U; Keitel V; Lohmeyer J; Simon KG; Trautwein C; Trein A; Hüppe D; Cornberg M; Lammert F; Ingiliz P; Zachoval R; Hinrichsen H; Zipprich A; Klinker H; Schulze Zur Wiesch J; Schmiedeknecht A; Brosteanu O; Berg T
J Hepatol; 2023 May; 78(5):926-936. PubMed ID: 37062574
[TBL] [Abstract][Full Text] [Related]
13. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.
Yuen MF; Agarwal K; Gane EJ; Schwabe C; Ahn SH; Kim DJ; Lim YS; Cheng W; Sievert W; Visvanathan K; Ruby E; Liaw S; Yan R; Huang Q; Colonno R; Lopatin U
Lancet Gastroenterol Hepatol; 2020 Feb; 5(2):152-166. PubMed ID: 31711752
[TBL] [Abstract][Full Text] [Related]
14. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Buti M; Gane E; Seto WK; Chan HL; Chuang WL; Stepanova T; Hui AJ; Lim YS; Mehta R; Janssen HL; Acharya SK; Flaherty JF; Massetto B; Cathcart AL; Kim K; Gaggar A; Subramanian GM; McHutchison JG; Pan CQ; Brunetto M; Izumi N; Marcellin P;
Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):196-206. PubMed ID: 28404092
[TBL] [Abstract][Full Text] [Related]
15. Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial.
Yuen MF; Zhou X; Gane E; Schwabe C; Tanwandee T; Feng S; Jin Y; Triyatni M; Lemenuel-Diot A; Cosson V; Xue Z; Kazma R; Bo Q
Lancet Gastroenterol Hepatol; 2021 Sep; 6(9):723-732. PubMed ID: 34237271
[TBL] [Abstract][Full Text] [Related]
16. Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy.
Chi H; Li Z; Hansen BE; Yu T; Zhang X; Sun J; Hou J; Janssen HLA; Peng J
Clin Gastroenterol Hepatol; 2019 Jan; 17(1):182-191.e1. PubMed ID: 29902645
[TBL] [Abstract][Full Text] [Related]
17. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.
Berg T; Simon KG; Mauss S; Schott E; Heyne R; Klass DM; Eisenbach C; Welzel TM; Zachoval R; Felten G; Schulze-Zur-Wiesch J; Cornberg M; Op den Brouw ML; Jump B; Reiser H; Gallo L; Warger T; Petersen J;
J Hepatol; 2017 Nov; 67(5):918-924. PubMed ID: 28736139
[TBL] [Abstract][Full Text] [Related]
18. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
[TBL] [Abstract][Full Text] [Related]
19. [A retrospective follow-up study of prolonged nucleos(t)ide analogue and interferon combination therapy in HBeAg-positive chronic hepatitis B patients].
Yu SL; Guo CY
Zhonghua Gan Zang Bing Za Zhi; 2013 Apr; 21(4):267-70. PubMed ID: 24021787
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients.
Hou J; Gane E; Balabanska R; Zhang W; Zhang J; Lim TH; Xie Q; Yeh CT; Yang SS; Liang X; Komolmit P; Leerapun A; Xue Z; Chen E; Zhang Y; Xie Q; Chang TT; Hu TH; Lim SG; Chuang WL; Leggett B; Bo Q; Zhou X; Triyatni M; Zhang W; Yuen MF
Clin Mol Hepatol; 2024 Apr; 30(2):191-205. PubMed ID: 38190830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
